araag2/TREC_Precision-Medicine huggingface dataset:
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Early Detection of Lung Tumors by Sniffer Dogs - Evaluation of Sensitivity and Specificity

Summary: Some groups reported that sniffer dogs can be applied to detect lung cancer in the exhaled breath of patients. Therefore, breath samples (BS) of patients are collected. Five sniffer dogs are trained to distinguish between the BS of patients with lung cancer and healthy individuals (controls). In a prospective, randomized blinded study the dog's ability to differentiate between BS of i) patients with lung cancer, ii) patients with inflammatory airway disease, but no evidence of cancer and iii) healthy individuals is tested.

Detailed description: All breath samples (BS) are collected in patients on the basis of radiologic findings before any intervention (bronchoscopy, biopsy or surgery) has been performed. The allocation to study groups is made following diagnostic work up and surgery.
  Three study groups are defined using the following inclusion and exclusion criteria:
  -  lung cancer: male & female, age 18-80, competent, confirmed lung cancer in diagnostic work up and surgery, no history or present other tumor disease
  -  healthy individual: male & female, age 18-80, competent, no history or present other tumor disease including lung cancer, no pathological lung function tests
  -  chronic obstructive lung disease: male & female, age 18-80, competent, no history or present other tumor disease including lung cancer, pathological lung function tests
  For each patient, i) history, ii) present medication, iii) lung function tests are documented. For the lung cancer patients, the tumor stage following surgery is documented.
  Five sniffer dogs are trained using BS of lung cancer patients and healthy individuals. After completion of the training the ability of the dogs to differentiate between the groups is tested:
  -  5 BS are presented in 1 experiment:
  -  Test I: lung cancer vs healthy individual
  -  Test II: lung cancer vs chronic obstructive pulmonary disease
  -  Test III: lung cancer vs healthy individuals & bronchitis
  -  for every experiment 1 BS of a lung cancer patient is used
  -  the lung cancer sample is placed randomly in one of the five test tubes
  -  the other test tubes are used for BS of healthy individuals or chronic obstructive pulmonary disease patients or both
  -  neither the dog handler nor the dog know the loading of the test tubes
  -  experiments are repeated 5 to 10 times
  For analysis, the sensitivity and specificity of the dog's reaction is determined.
  The patient's medication, smoking habits, age and gender are analysed to rule out confounders or bias.

Eligibility: Inclusion Criteria:
  -  age 18-80
  -  competent
  -  confirmed lung cancer
  Exclusion Criteria:
  -  history of other cancers

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Tyrosine Kinase Inhibitors In Metastatic Non Small Cell Lung Cancer

Summary: Aim of the present retrospective study is to evaluate molecular factors of primary resistance to tyrosine kinase inhibitors in metastatic non small cell lung cancer (NSCLC) patients. The investigators assess first, the incidence of epidermal growth factor receptor (EGFR) and Kirsten ras sarcoma viral oncogene homolog (KRAS) mutations, SOS and hepatocyte growth factor (HGF) expression, anaplastic lymphoma kinase (ALK) translocation and expression and, secondly, the investigators correlate molecular markers with clinical features and outcome in terms of response rate, progression free survival and overall survival.

Detailed description: Non small cell lung cancer patients.

Eligibility: Inclusion Criteria:
  -  Histologically confirmed diagnosis of NSCLC (non small cell lung cancer) with available tumor tissue for mutational analysis
  -  Metastatic disease treated with gefitinib or erlotinib
  -  Presence of at least one measurable lesion according to RECIST criteria
  Exclusion Criteria:
  -  No tumor tissue available
  -  No clinical data available

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Lung Inflammation and Lung Metastases From Breast Cancer

Summary: The purpose of this study is to find out if there is a link between cigarette smoking, inflammation and the spread of breast cancer to the lung. We think that women who are current or former smokers may be at increased risk for breast cancer spreading to the lung compared to women who have never smoked. Smoking causes inflammation in the lung in some women. Researchers at Memorial Sloan-Kettering (MSKCC) think that smoking-related lung inflammation may increase the chance of breast cancer spreading to the lung. In order to find out whether inflammation plays a role in breast cancer spreading to the lung, we will measure a urinary marker of lung inflammation. This will allow us to determine if this marker is more commonly elevated in women with breast cancer that has spread to the lung compared to those without breast cancer in the lung. We will also collect DNA from blood to have the opportunity to determine if there are differences in DNA in women with or without breast cancer that has spread to the other sites including the lung. We will also collect blood to determine if we can identify risk factors for the spread of breast cancer to the lungs.


Eligibility: Inclusion Criteria:
  -  Registered patient at MSKCC
  -  Histologically proven breast cancer. It is not necessary that pathology be reviewed at MSKCC
  -  Age ≥18 years Group 1 (A and B)
  -  Diagnosed with metastatic breast cancer on biopsy or imaging study.
  -  Patients will be considered to have lung metastases, and will be assigned to group 1A if any of the following criteria are met, otherwise patients will be assigned to group 1B "No known Lung Metastases," Biopsy-proven lung metastasis.
  -  Pleural effusion with cytologic evidence of malignancy.
  -  Pleural effusion, exudative in character, without alternative explanation and attributed, in the opinion of the clinician to metastatic disease.
  -  Symptoms attributable to lung metastases and a radiological pattern interpreted by a radiologist as suspicious for metastatic disease.
  -  Any pulmonary nodule on chest radiograph, CT scan, PET-CT or MRI, which is interpreted by the clinician and radiologist to be metastatic in etiology, whether or not a biopsy was performed, and regardless of symptoms.
  -  A radiographic pattern interpreted by a radiologist as consistent with lymphangitic carcinomatosis.
  Group 2 (Controls)
  -  History of early breast cancer and currently no evidence of disease
  Exclusion Criteria:
  -  Inability to provide written informed consent.
  -  Inability to complete smoking and NSAID questionnaire.
  -  Steroid use within the previous 4 weeks.
  -  Radiotherapy to the breast, chest wall or axilla within the previous 3 months.
  -  Men with breast cancer.

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Studies Examining the Importance of Smoking After Being Diagnosed With Lung Cancer

Summary: A large project consisting of:
  a) an observational trial where smoking status is recorded on 1400 consecutive people newly diagnosed with lung cancer. Smoking status is biologically validated with exhaled carbon monoxide (eCO) levels every 3 months. Survival, cancer progression and treatment complications will be recorded and compared in smokers, ex-smokers and never smokers.

Detailed description: Smoking causes around 85% of lung cancer. Continued smoking after diagnosis probably worsens survival and increases treatment complications but prospective well-designed studies are lacking.
  This project is an observational cohort study recording outcomes in smokers, never-smokers, and ex-smokers, using exhaled carbon monoxide to validate smoking status when they attend for further lung cancer clinics.
  This project is unique, as every patient with a clinical diagnosis of lung cancer will have their smoking status biologically validated by a quick and easy test, and those enrolled in the smoking cessation treatments or not will also complete a generic quality of life questionnaire at regular intervals. These appointments will coincide with other hospital appointments wherever possible, and survival status will reported up to 24 months after enrolment.

Eligibility: Inclusion Criteria:
  -  clinical diagnosis of lung cancer
  Exclusion Criteria:
  -  refusal Consent
  -  inability to provide exhaled CO
  -  active psychiatric illness or substance misuse
  -  concurrent malignancies of another type other than non-melanoma skin cancer
  -  unable to travel for sessions with smoking cessation counsellor and / or outpatient visits from outset
  -  WHO performance status 4
  -  Life expectancy less than 6 weeks.

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Summary: RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet known whether sunitinib is effective in treating non-small cell lung cancer.
  PURPOSE: This phase II trial is studying sunitinib to see how well it works when given as maintenance therapy in treating patients with stage III or stage IV non-small cell lung cancer which is previously treated with combination chemotherapy.

Detailed description: OBJECTIVES:
  Primary
  -  To investigate the effect of sunitinib malate on the progression-free survival of patients with stage IIIB or IV non-small cell lung cancer Secondary
  -  To evaluate the toxicity of sunitinib when administered in the maintenance setting.
  -  To evaluate the additional response rate to sunitinib malate when administered in the maintenance setting.
  -  To evaluate the overall survival of patients treated with sunitinib. After completion of study treatment, patients are followed every 2 months for 1 year, every 6 months for 1 year, and periodically for 3 years.

Eligibility: Inclusion Criteria:
  -  No evidence of symptomatic or untreated brain metastases, spinal cord compression, or carcinomatous meningitis
  -  Histologically or cytologically confirmed primary non-small cell lung cancer who have stable or responding disease after prior treatment with 3-6 courses of platinum -based therapy
  -  Not a candidate for combined modality therapy
  -  No cavitary lesions
  Exclusion Criteria:
  -  Evidence of symptomatic or untreated brain metastases, spinal cord compression, or carcinomatous meningitis

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Cardiovascular Prophylaxis for Postmenopausal Women

Summary: The purpose of this study was to examine the effect of 6 months moderate intensity exercise training completed three times per week upon traditional and emerging cardiovascular disease risk factors in postmenopausal women both with and without type 2 diabetes. These risk factors include blood markers associated with increased risk such as cholesterol, insulin, glucose and markers of inflammation plus measures of body fat, heart and lung fitness, vascular stiffness and vascular function. The study hypothesised that moderate intensity exercise training would intervene in the exaggerated risk seen in women following the menopause, especially in those with type 2 diabetes.


Eligibility: Inclusion Criteria:
  -  Healthy and stable type II diabetic postmenopausal women (cessation of menstrual periods for 12 months and confirmed with LH/FSH samples) aged 45 − 65 years old for the cross sectional analysis and exercise training study.
  Exclusion Criteria:
  -  Identified abnormalities during baseline testing.
  -  Vigorously active women.
  -  Women who are pregnant.
  -  Women with serious systemic or psychological disorders (e.g. COPD, asthma, clinical depression).
  -  Women with known coronary artery disease.
  -  Women with significant cardiovascular pathologies and associated medication.
  -  Women with type 1 or insulin treated diabetes.
  -  Women with diabetes with complications.
  -  Women with unstable diabetes or hypertension.
  -  Women with any cancer.
  -  Women with musculoskeletal impairments or contraindications to exercise.

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Acetyl-L-Carnitine Reduces Depression and Improves Quality of Life in Patients With Minimal Hepatic Encephalopathy

Summary: Minimal hepatic encephalopathy represents a common complication present in well-compensated cirrhotic patients that impairs patients daily functioning and health-related quality of life. Acetyl-L-carnitine has been shown to be useful in improving blood ammonia and cognitive functions in cirrhotic patients with minimal hepatic encephalopathy. This study evaluated the effects of acetyl-L-carnitine treatment on health related quality of life and on depression in patients with minimal hepatic encephalopathy.


Eligibility: Inclusion Criteria:
  -  All patients diagnosed as having cirrhosis at the outpatient Internal Medicine of the Department of Senescence of Cannizzaro Hospital (Catania) were candidates for enrolment. The diagnosis of cirrhosis was based on clinical, biochemical and ultrasonographic or liver histological data.
  Exclusion Criteria:
  -  Exclusion criteria were overt hepatic encephalopathy or a history of overt HE; history of recent alcohol intake; infection; recent antibiotic use or gastrointestinal bleeding; history of recent use of drugs affecting psychometric performances like benzodiazepines, antiepileptics or psychotropic drugs; a history of shunt surgery or transjugular intrahepatic portosystemic shunt for portal hypertension; electrolyte imbalance; renal impairment; hepatocellular carcinoma; severe medical problems such as congestive heart failure, pulmonary disease or neurological or psychiatric disorder that could influence quality of life measurement; inability to perform neuropsycological tests.

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Using Videos in Advance Care Planning for Patients With Advanced Cancer

Summary: To compare the decision making of subjects with advanced cancer having a verbal advance care planning discussion compared to subjects using a video.

Detailed description: A.1. Aim 1: To recruit 150 subjects with advanced cancer and randomly assign these subjects to one of two advance care planning (ACP) modalities: 1. a video visually depicting CPR (intervention) or 2. a verbal narrative describing the CPR.
  Hypothesis 1: It is feasible to recruit and randomize 150 subjects with advanced cancer.
  A.2. Aim 2: To compare the care preferences for CPR among 150 subjects randomized to video vs. verbal narrative intervention.
  Hypothesis 2: Subjects randomized to the video intervention will be significantly more likely to opt NOT to have CPR compared to those randomized to the verbal narrative.
  A.3. Aim 3: To compare knowledge assessment of CPR for 150 subjects randomized to video vs. verbal narrative intervention.
  Hypothesis 3: When compared to subjects randomized to the verbal narrative arm, subjects in the video group will have higher knowledge assessment scores when asked questions regarding their understanding of CPR.

Eligibility: Inclusion Criteria:
  1. diagnosis of cancer that falls under one of the following: A. All patients with brain cancer, inoperable hepatocellular/bile duct/gallbladder cancer, incurable non-small cell lung carcinoma (wet IIIb or IV), extensive stage small cell lung cancer, inoperable mesothelioma, inoperable pancreatic cancer or; metastatic gastric or esophageal cancer, metastatic melanoma, OR B. Patients with the following cancers, if first-line therapy has failed and limited response is expected to second-line therapy: breast cancer, colorectal cancer, head and neck cancer, leukemia, ovarian cancer, prostate cancer, renal cancer, sarcoma, lung cancer, myeloma, or lymphoma, OR C. Less than one year prognosis.
  2. ability to provide informed consent,
  3. cognitive ability to participate in the study
  4. ability to communicate in English.
  Exclusion Criteria:
  1. inability to make decisions,
  2. non-English speaking,
  3. new patient visit

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Safety Study of TRK-820 for Patient With Hemodialysis

Summary: The purpose of this study is to observe pharmacokinetics and safety of nalfurafine hydrochloride in patients receiving hemodialysis.


Eligibility: Inclusion Criteria:
  -  Patients with chronic renal failure who receive dialysis three times a week on a regular basis and do not expect an important change in treatment nor a rapid change in conditions
  -  Patients aged 20 years or older
  -  Patients whose post-dialysis BMI measured at the nearest time before the singing day is in the range of 70 ~ 130 %
  -  Patients who can understand and follow instructions and participate in the study during the entire study period
  -  Patients who signed the informed consent form before participating in the study
  Exclusion Criteria:
  -  Patients who have confirmed malignant tumor
  -  Patients with cognitive impairment including depression, schizophrenia and dementia
  -  Patients with hepatic cirrhosis as a complication
  -  Patients with drug allergy to opioids
  -  Patients with drug dependency or allergic disease (including skin response to UV radiation)
  -  Patients who participated in other study and received the investigational drug within 1 month before the signing day
  -  Patients who participated in other TRK-820 study within 4 weeks before the signing day
  -  Pregnant or lactating women or premenopausal women of childbearing potential who do not conduct contraception
  -  Patients who received any of the following drugs within 2 weeks before Day 1
  1. Azole antifungal agents
  1. Ketoconazole
  2. Fluconazole
  3. Itraconazole
  4. Clotrimazole
  2. Macrolide antibiotics
  1. Erythromycin
  2. Midecamycin
  3. Josamycin
  4. Roxithromycin
  5. Clarithromycin
  6. Triacetyloleandomycin
  3. Ritonavir
  4. Cyclosporine
  5. Nifedipine
  6. Cimetidine
  7. Amiodarone
  -  Patients who had the following drinks and foods within 2 weeks before Day 1
  1. Foods and drinks containing grape fruit juice
  2. Food and drinks containing St. John's wort
  -  Patients who participated in other clinical study during the period between the singing day and hospitalization (Day 1)
  -  Patients who smoked and drank from three months before the signing day
  -  Patients who are ineligible for the clinical study for other reasons at the investigator's discretion

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: GWAS Research of Lung Cancer in Tianjin

Summary: To study the association of Genetic Polymorphisms with Lung Cancer Risk in Tianjin Population.

Detailed description: Eligibility criteria:
  -  nonsmoker
  -  female
  -  age between 35 and 80
  -  no other types of tumors history
  -  frequency-matched cases and controls on gender and age
  Outcome measures:
  -  OR(odds ratio)
  -  RR(risk ratio)
  -  CI(confidence interval)
  -  SAS software

Eligibility: Inclusion Criteria:
  -  Non-small cell lung cancer
  -  Age from 35 to 80 years old
  -  Female
  -  Non-smokers
  -  Frequency-matched on age and gender
  Exclusion Criteria:
  -  Previous medical history of cancer
  -  Previous radiotherapy
  -  Previous chemotherapy

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Lung Cancer Rehabilitation Study

Summary: Patients suffering from non small cell lung cancer(NSCLC), depend upon lung removal to increase their chances of survival. But, this type of surgery cannot be advised to patients with significant heart disease, limited lung fuction or reduced physical fitness. Intensive physical training has been shown to increase aerobic fitness in healthy subjects.
  The purpose of this study is to determine the effect of a short term rehabilitation prior to surgery on the post-operative and physiological outcomes for patients undergoing this type of surgery.

Detailed description: For patients with non small cell lung cancer (NSCLC), lung resection surgery is the only treatment option which increases survival. However, surgery can not be offered to those with significant heart disease, limited lung function or lacking physical fitness. These are all major risk factors for operative outcome. Cardio-pulmonary exercise testing (CPET) allows direct measurement of aerobic physical fitness through maximal oxygen consumption (VO2 max). A recent update of professional guidelines (ERS/ESTS) has emphasized the importance of CPET in preoperative risk stratification of patients with NSCLC. Interestingly, intensive physical training has been shown to increase aerobic fitness in animals and healthy subjects whereas improvement of VO2 max has been observed in preliminary pilot studies conducted in patients undergoing surgery for NSCLC. However, the net effect of short-term, intensive, outpatient rehabilitation on clinically relevant outcomes, such as major post-operative cardio-pulmonary complications, as well as physiological outcomes is unknown.
  Objectives:
  1. To assess the physiological effect of 3 weeks of intensive physical training in patients eligible for NSCLC surgery.
  2. To assess the effect of physical training on post-operative outcomes.
  3. To identify the clinical variables, laboratory tests and specific gene polymorphisms (SNPs) associated with these outcomes.

Eligibility: Inclusion Criteria:
  Proven or suspected lung cancer, stage III A or less (eligible for surgical cure), documented by CT-scan or Positron Emission Tomography CT scan (PET-CT)
  Exclusion Criteria:
  -  Contra-indication to perform cardio-pulmonary exercise test (uncontrolled cardiac disease, severe pulmonary hypertension, osteo-articular limitations impeding cycling)
  -  Inability to adhere to rehabilitation program (because of clinically limiting comorbidity, psychiatric condition or osteoarthritis)
  -  Clinically limiting or untreated heart disease

Relevance to patient case: not relevant